Esperion Expands Bempedoic Acid Data with Pediatric and Adult LDL-C Reduction Findings

Event summary

  • Esperion will present two new analyses on bempedoic acid at EAS Congress 2026, including a pediatric Phase 2 study and CLEAR Outcomes trial insights.
  • Pediatric study shows LDL-C reductions in children with HeFH consistent with adult results, supporting Phase 3 development.
  • New analysis identifies patient characteristics associated with ≥30% LDL-C reductions in statin-intolerant patients.
  • Presentations occur May 25, 2026, in Athens, Greece.

The big picture

Esperion's data expansions position bempedoic acid as a potential cornerstone in both adult and pediatric LDL-C management, addressing unmet needs in statin-intolerant populations. The findings come as the cardiovascular therapeutics sector increasingly focuses on precision approaches to lipid management. With global approvals in over 40 countries, Esperion is leveraging these insights to strengthen its commercial position and partnership potential.

What we're watching

Pediatric Market Expansion
Whether Esperion can successfully transition bempedoic acid into Phase 3 pediatric development and secure approvals for HeFH and HoFH.
Clinical Utilization
How the identified patient characteristics for enhanced LDL-C reduction will impact real-world prescribing patterns.
Competitive Positioning
The pace at which Esperion can differentiate bempedoic acid in the growing non-statin LDL-C lowering market.